#ESMO19 – [Abstract Only] Randomized Trial: Improved Overall Survival at 5 Years with Combined Immunotherapy for Advanced Melanoma
30 Sep, 2019 | 00:37h | UTCFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries: Skin cancer: Half of people surviving advanced melanoma – BBC (free) AND Combination immunotherapy drugs herald new hope for melanoma patients with long term survival rates – The Royal Marsden NHS Foundation Trust (free)
#ESMO19 – Just presented at the European Society of Medical Oncology Congress 2019 in Barcelona
Related Commentary on Twitter
With a 5-year min follow-up, the combination of nivolumab plus ipilimumab associated with 5-year survival of 52% in patients with metastatic #melanoma, compared with 44% for nivolumab alone and 26% for ipilimumab alone. See the CheckMate 067 trial. #ESMO19 https://t.co/f50KNzH5tp
— NEJM (@NEJM) September 28, 2019